ISSN 1662-4009 (online)

ey0016.3-10 | New Genes | ESPEYB16

3.10. Mutations in IRS4 are associated with central hypothyroidism

CA Heinen , EM de Vries , M Alders , H Bikker , N Zwaveling-Soonawala , Akker ELT van den , B Bakker , G Hoorweg-Nijman , F Roelfsema , RC Hennekam , A Boelen , Trotsenburg ASP van , E Fliers

To read the full abstract: J Med Genet. 2018;55:693–700.This genetic study identified, by whole exome sequencing, mutations in the insulin receptor substrate 4 gene (IRS4) in 5 families with isolated central congenital hypothyroidism. Thus, the authors add a fifth genetic cause of isolated congenital hypothyroidism to the previously known genes: TSHB, TRHR, IGSF1, ...

ey0016.4-11 | New Mechanisms | ESPEYB16

4.11. Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice

K Mao , GF Quipildor , T Tabrizian , A Novaj , F Guan , RO Walters , F Delahaye , GB Hubbard , Y Ikeno , K Ejima , P Li , DB Allison , H Salimi-Moosavi , PJ Beltran , P Cohen , N Barzilai , DM Huffman

To read the full abstract: Nat Commun. 2018 19;9:2394.“Somatopause” causes the physiological decline over time in GH secretion leading to low IGF-I levels in aging subjects. GH has been proposed as an anti-aging therapy, but with no evidence of beneficial effects and with some potential risks [1,2]. Therefore, current guidelines do not recommend GH therapy as anti-aging treatme...

ey0016.6-2 | New Functions of (Old) Genes | ESPEYB16

6.2. Epigenetic repression of androgen receptor transcription in mutation-negative androgen insensitivity syndrome (AIS type II)

NC Hornig , P Rodens , H Dorr , NC Hubner , AE Kulle , HU Schweikert , M Welzel , S Bens , O Hiort , R Werner , S Gonzalves , AK Eckstein , M Cools , A Verrijn-Stuart , HG Stunnenberg , R Siebert , O Ammerpohl , PM Holterhus

J Clin Endocrinol Metab. 2018 Dec 1;103(12):4617–4627.doi: 10.1210/jc.2018-00052. PMID: 30124873This study shows for the first time that epigenetic changes in the androgen receptor gene (AR) proximal promoter region may underlie a clinical phenotype of Androgen Insensitivity Syndrome (AIS) in individuals in whom no DNA sequence mutation in AR or ...

ey0016.7-6 | Genetics of Puberty | ESPEYB16

7.6. Elucidating the genetic architecture of reproductive ageing in the Japanese population

M Horikoshi , FR Day , M Akiyama , M Hirata , Y Kamatani , K Matsuda , K Ishigaki , M Kanai , H Wright , CA Toro , SR Ojeda , A Lomniczi , M Kubo , KK Ong , JRB Perry

To read the full abstract: Nat Commun. 2018 May. 17;9(1):1977.This population study reports 26 loci for ages at menarche and menopause in a Japanese population and demonstrates widespread differences in allele frequencies and effect estimates between Japanese and European variants.Over the past decade, genome-wide association study (GWAS) meta-analys...

ey0016.7-15 | Treatment | ESPEYB16

7.15. Letrozole versus testosterone for promotion of endogenous puberty in boys with constitutional delay of growth and puberty: a randomised controlled phase 3 trial

T Varimo , H Huopio , L Kariola , S Tenhola , R Voutilainen , J Toppari , S Toiviainen-Salo , E Hamalainen , MA Pulkkinen , M Laaperi , A Tarkkanen , K Vaaralahti , PJ Miettinen , M Hero , T Raivio

To read the full abstract: Lancet Child Adolesc Health. 2019 Feb;3(2):109–120This randomised, controlled, open-label trial at four paediatric centres in Finland evaluates aromatase inhibition with letrozole to induce puberty in boys with constitutional delay of growth and puberty.Treatment of delayed puberty aims to promote pubertal development ...

ey0016.9-15 | Biologic Agents and Growth in Chronic Inflammatory Diseases | ESPEYB16

9.15. Growth during Tocilizumab therapy for Polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial

KN Bharucha , HI Brunner , I Calvo Penades , I Nikishina , N Rubio-Perez , S Oliveira , K Kobusinska , H Schmeling , F Sztajnbok , F Weller-Heinemann , E Zholobova , F Zulian , R Allen , J Chaitow , J Frane , C Wells , N Ruperto , F De Benedetti

To read the full abstract: J Rheumatol. 2018; 45(8): 1173In recent years, biologic agents have clearly been shown to be effective in maintaining remission and improving linear growth in children with inflammatory bowel disease and other chronic inflammatory diseases (1–3). This prospective cohort study analyzed growth in 187 patients (143 females, mean age 11±4 years; including...

ey0016.11-1 | New Insights into Body Weight Regulation | ESPEYB16

11.1. Genetic architecture of human thinness compared to severe obesity

F Riveros-McKay , V Mistry , R Bounds , A Hendricks , JM Keogh , H Thomas , E Henning , LJ Corbin , Understanding Society Scientific Group , S O'Rahilly , E Zeggini , E Wheeler , I Barroso , IS Farooqi

To read the full abstract: PLoS Genet. 2019; 15(1):e1007603.This genome wide association study reveals new insights into the genetic basis of thinness by investigating a large cohort of healthy persistently thin individuals. In the past, it has been speculated that inheritance of thinness may constitute a protective factor against environmental factors disposing to obesity (1). Neverthel...

ey0016.11-4 | New Insights into Body Weight Regulation | ESPEYB16

11.4. Dysregulation of a long noncoding RNA reduces leptin leading to a leptin-responsive form of obesity

OS Dallner , JM Marinis , YH Lu , K Birsoy , E Werner , G Fayzikhodjaeva , BD Dill , H Molina , A Moscati , Z Kutalik , P Marques-Vidal , TO Kilpelainen , N Grarup , A Linneberg , Y Zhang , R Vaughan , RJF Loos , MA Lazar , JM Friedman

To read the full abstract: Nature Medicine 2019; 25(3):507-516.This paper shows that quantitative leptin expression is controlled by redundant cis elements and trans factors that interact with the proximal promoter together with a long noncoding RNA.Friedman’s research group discovered the adipocyte hormone leptin more than 20 years ago. They identified loss o...

ey0016.12-5 | Type 2 Diabetes | ESPEYB16

12.5. Liraglutide in children and adolescents with type 2 diabetes

WV Tamborlane , M Barrientos-Perez , U Fainberg , H Frimer-Larsen , M Hafez , PM Hale , MY Jalaludin , M Kovarenko , I Libman , JL Lynch , P Rao , N Shehadeh , S Turan , D Weghuber , T Barrett , I Ellipse Trial

N Engl J Med 2019; 10.1056/NEJMoa1903822.DOI: 10.1056/NEJMoa1903822http://www.ncbi.nlm.nih.gov/pubmed/31034184Summary: In a double-blind, randomized, phase 3 trial, 135 overweight and obese adolescents, aged 10 to 17 years with T2DM, were randomly assigned to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo, bot...

ey0016.12-13 | Lipid Metabolism | ESPEYB16

12.13. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer

JE Manson , NR Cook , IM Lee , W Christen , SS Bassuk , S Mora , H Gibson , CM Albert , D Gordon , T Copeland , D D'Agostino , G Friedenberg , C Ridge , V Bubes , EL Giovannucci , WC Willett , JE Buring , VITAL Research Group Buring

To read the full abstract: N Engl J Med 2019;380:23-32.Summary: In this randomized primary prevention placebo-controlled trial of 25,871 US adults, with a two-by-two factorial design, supplements with omega-3 did not lower the overall incidence of adverse cardiovascular events or cancer compared to a placebo.Comment: Omega-3 fatty acids are polyun...